Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILVER study of quetiapine SR for generalized anxiety disorder
2005-005054-46Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Quetiapine SR, Placebo and Paroxetine active control (3 arms). Primary endpoint: Change from randomization in Hamilton Anxiety Rating Scale total score at Day 57. Started Jan 2006; status: completed.
02
Drugs
quetiapineparoxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2005-005054-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005054-46.